Who Paid My Doc
Rebecca Lord
Nurse Practitioner, Adult Health Richmond, VA Nurse Practitioner
NPI 1215227145 CMS profile 11230065
2105 E Parham Rd, Richmond, VA 23228
General payments
$8,470
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Rebecca Lord of Richmond, VA is reported in the CMS Open Payments database as having received $8,470 across 363 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,412 | 53 | |
| 2024 | General | $1,832 | 80 | |
| 2023 | General | $1,451 | 71 | |
| 2022 | General | $1,799 | 75 | |
| 2021 | General | $1,976 | 84 |
Beside peers
- Rebecca Lord
- Nurse Practitioner, Adult Health median
- Middle half of Nurse Practitioner, Adult Health
- National median
In program year 2025, general payments to Rebecca Lord were reported at $1,412. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.
Show as a table
| Year | Rebecca Lord | Nurse Practitioner, Adult Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $1,976 | $138 | $43–$438 | $132 |
| 2022 | $1,799 | $165 | $54–$494 | $149 |
| 2023 | $1,451 | $178 | $61–$549 | $160 |
| 2024 | $1,832 | $186 | $62–$575 | $164 |
| 2025 | $1,412 | $184 | $59–$580 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 49 drugsPart D claims
2,119
Drug cost
$969,859
Branded share of claims
68.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | Brand | 201 | $264,961 | |
| Ozempic Semaglutide | Brand | 145 | $184,921 | |
| Jardiance Empagliflozin | Brand | 62 | $73,181 | |
| Xigduo Xr Dapaglifloz Propaned/Metformin | Brand | 56 | $52,687 | |
| Trulicity Dulaglutide | Brand | 40 | $50,548 | |
| Farxiga Dapagliflozin Propanediol | Brand | 48 | $48,513 | |
| Synjardy Xr Empagliflozin/Metformin Hcl | Brand | 32 | $36,214 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 60 | $34,967 | |
| Januvia Sitagliptin Phosphate | Brand | 31 | $30,379 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 28 | $20,594 |
The 10 drugs with the highest cost, of 49 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 21 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Wegovy |
|
$151 | — | — |
| FARXIGA |
|
$145 | 48 | — |
| GVOKE HYPOPEN |
|
$125 | — | — |
| Ozempic |
|
$92 | 145 | — |
| JARDIANCE |
|
$76 | 62 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 21 in the dashboard with a free accountRecords
363 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Adult Health in Virginia
Christine Kessler
Nurse Practitioner, Adult Health · Fort Belvoir, VA
Denise Bruen
Nurse Practitioner, Adult Health · Charlottesville, VA
Theresa Harrington Stukus
Nurse Practitioner, Adult Health · Fairfax, VA
Chelsea Koskovich
Nurse Practitioner, Adult Health · Fredericksburg, VA
Brittany Brown
Nurse Practitioner, Adult Health · Lynchburg, VA
Colleen Diering
Nurse Practitioner, Adult Health · Virginia Beach, VA
Related records
Nurse Practitioner, Adult Health in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Adult Health
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.